In 1843 the Englishman William Brockedon (1787 - 1854) applied for a patent for the tablet and caused “one of the most tremendous upheavals that the pharmacists have ever experienced”. Thereby active ingredients can be precisely dosed and are very stable, the taking is convenient, the production cheap and they are easy to transport. As a result, tablets occupy a special position today with a share of almost 50% among the drug forms.
A trend that we are seeing in the market in the USA is the improvement of patient compliance. "Take 1 tablet instead of having to think about regularly taking 3 tablets a day." A trend that we are seeing in the USA addresses just this topic. The goal is to ensure the release of the active ingredients over a longer period after administration. This enables longer intervals between doses and, as a result, improved quality of personal life and an increased chance of successful treatment.
Lanolin or wool wax is a versatile ingredient and was used medicinally in ancient times. Lanolin is the secretion from sebum glands of sheep and is formed on the surface of their skin. However, the animals have to be treated with pesticides to protect them from parasites. The problem here is that these pesticides accumulate in the wool wax and can later lead to strong allergic reactions in users. This motivated IOI Oleo GmbH to develop a plant-based, synthetic alternative: et voila, SOFTISAN® 649 has since enriched our portfolio and has, among other things, made a name for itself as a lanolin substitute in the pharmaceutical industry.
An infusion can save lives and is used as a basic therapy in all areas of health care. The therapy, however, is complex and error-prone. Just as the patient relies on the correct diagnosis by the doctor and the proper execution by the specialist staff, so must the doctor and specialist staff rely on the quality of the infusions. With the MIGLYOL® product portfolio, the Pharma business unit of IOI Oleo GmbH offers high-quality carriers for injectables (infusions and injections).
In the early 2000s, the team of the IOI Oleo GmbH Pharma Business Unit asked themselves: Why do the principles and guidelines for active ingredients not also apply to excipients? As a result, the production site in Witten was GMP-certified, making IOI Oleo GmbH one of the first manufacturers of excipients to be GMP-certified. The certificate was recently confirmed again.
Medical applications and research have recently put cannabis in the spotlight and fueled a boom in demand. We now speak of a "green rush" - but what exactly triggered this demand? It is worth taking a closer look.
Hardly any other area today is as highly regulated by the legislature as the pharmaceutical industry. However, there are currently no manufacturing guidelines for lipid-based excipients, although most drugs consist for the largest part (75 to 99%) of excipients. The team of the Pharma Business Unit at IOI Oleo GmbH is aware of its responsibility as a globally known provider of oleochemical specialties for pharmaceuticals. We were the first company to receive a GMP certificate for our excipients, although this is only required for active ingredients.
"The hard fat with a difference?" - SOFTISAN® 378 of the IOI Oleo GmbH corresponds to the properties of hard fat according to the official monograph. In this blog post you will experience what is actually hidden behind the product and what its special properties are.
The team in the Pharma Business Unit has made a name for itself throughout the world with the most diverse products under the WITEPSOL® brand. Whereas, the WITEPSOL® brand name has practically become a synonym for hard fat. How did we achieved that? You will find out in this blog post.
We got off to a running start in preparing for the CPhI Worldwide and intended to proudly present our new Corporate Design there, together with our completely revised catalogues. But, as everyone knows, all trade fairs were cancelled; we are therefore using this medium to bring you closer to our new look and feel.